Silver Book Fact

Economic value from flu vaccine in elderly

As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest economic benefit.

Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, et al. The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs. Vaccine. 2007; 25: 5086-96. http://download.thelancet.com/flatcontentassets/H1N1-flu/epidemiology/epidemiology-14.pdf

Reference

Title
The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs
Publication
Vaccine
Publication Date
2007
Authors
Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, et al.
Pages
5086-96
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Mortality from vaccine-preventable diseases
    Vaccine-preventable diseases or their complications account for 50,000 to 90,000 adult deaths in the U.S. each year.  
  • Potential savings from shingles vaccine
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
  • Savings from flu vaccine
    Vaccination for influenza resulted in an average annual cost savings of $13.66 per healthy working adult vaccinated.  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.  
  • Staff vaccination in nursing homes reduces mortality rates of residents
    Mortality rates in nursing home residents were 42% lower in facilities with higher staff vaccination coverage compared with control facilities.